LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) announced the availability of its intranasal flu vaccine for the 2021-2022 influenza season. The company said the bulk of its supply of FLUMIST QUADRIVALENT vaccine for the season is expected to be available by mid-September.
The company noted that FLUMIST QUADRIVALENT is the only FDA-approved flu vaccine to use a needle-free nasal spray administrative technique. It is indicated for people ages 2 through 49. The common side effects of this vaccine are runny or stuffy nose, sore throat, and fever over 100F.
Copyright RTT News/dpa-AFX
© 2021 AFX News
